Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 507265, 8 pages
http://dx.doi.org/10.1155/2015/507265
Research Article

Association of Plasma Adiponectin and Oxidized Low-Density Lipoprotein with Carotid Intima-Media Thickness in Diabetic Nephropathy

1Laboratory of Pharmacology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece
2Department of Nephrology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece
3Second Department of Internal Medicine, Diabetes Clinic, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece

Received 17 December 2014; Revised 8 April 2015; Accepted 22 April 2015

Academic Editor: Ponnusamy Saravanan

Copyright © 2015 Anna Tavridou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Bojestig, H. J. Arnqvist, G. Hermansson, B. E. Karlberg, and J. Ludvigsson, “Declining incidence of nephropathy in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 330, no. 1, pp. 15–18, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. M. K. Arora and U. K. Singh, “Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update,” Vascular Pharmacology, vol. 58, no. 4, pp. 259–271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Wada and H. Makino, “Inflammation and the pathogenesis of diabetic nephropathy,” Clinical Science, vol. 124, no. 3, pp. 139–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Sharma, S. RamachandraRao, G. Qiu et al., “Adiponectin regulates albuminuria and podocyte function in mice,” The Journal of Clinical Investigation, vol. 118, no. 5, pp. 1645–1656, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. I. Yilmaz, M. Saglam, A. R. Qureshi et al., “Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin,” Nephrology Dialysis Transplantation, vol. 23, no. 5, pp. 1621–1627, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Ran, X. Xiong, W. Liu et al., “Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients with diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 88, no. 2, pp. 177–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Miyagishima, S. Hiramitsu, S. Kato et al., “Efficacy of atorvastatin therapy in ischaemic heart disease—effects on oxidized low-density lipoprotein and adiponectin,” Journal of International Medical Research, vol. 35, no. 4, pp. 534–539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Saito, O. Saito, T. Kawano et al., “Elevation of serum adiponectin and CD146 levels in diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 78, no. 1, pp. 85–92, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Jorsal, L. Tarnow, J. Frystyk et al., “Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy,” Kidney International, vol. 74, no. 5, pp. 649–654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. G. A. Christou and D. N. Kiortsis, “The role of adiponectin in renal physiology and development of albuminuria,” Journal of Endocrinology, vol. 221, no. 2, pp. R49–R61, 2014. View at Publisher · View at Google Scholar
  11. N. Sweiss and K. Sharma, “Adiponectin effects on the kidney,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 28, no. 1, pp. 71–79, 2014. View at Google Scholar · View at Scopus
  12. C. Zoccali and F. Mallamaci, “Adiponectin and renal disease progression: another epidemiologic conundrum?” Kidney International, vol. 71, no. 12, pp. 1195–1197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Gin, V. Rigalleau, and M. Aparicio, “Lipids, protein intake, and diabetic nephropathy,” Diabetes & Metabolism, vol. 26, no. 4, pp. 45–53, 2000. View at Google Scholar · View at Scopus
  14. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, “Oxidative stress as a major culprit in kidney disease in diabetes,” Diabetes, vol. 57, no. 6, pp. 1446–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Gutwein, M. S. Abdel-Bakky, K. Doberstein et al., “CXCL16 and oxLDL are induced in the onset of diabetic nephropathy,” Journal of Cellular and Molecular Medicine, vol. 13, no. 9B, pp. 3809–3825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Ujihara, Y. Sakka, M. Takeda et al., “Association between plasma oxidized low-density lipoprotein and diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 58, no. 2, pp. 109–114, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Ribeiro, M. D. S. Faria, G. Silva et al., “Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene,” Hemodialysis International, vol. 16, no. 4, pp. 481–490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Wang, D. Wang, Y. Zhang, X. Wang, Y. Liu, and M. Xia, “Adiponectin increases macrophages cholesterol efflux and suppresses foam cell formation in patients with type 2 diabetes mellitus,” Atherosclerosis, vol. 229, no. 1, pp. 62–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Lautamäki, T. Rönnemaa, R. Huupponen et al., “Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease,” Metabolism: Clinical and Experimental, vol. 56, no. 7, pp. 881–886, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Chitalia, R. B. Raja, T. Bhandara et al., “Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation,” Journal of Nephrology, vol. 23, no. 1, pp. 77–84, 2010. View at Google Scholar · View at Scopus
  21. A. Lisowska, W. J. Musiał, P. Lisowski, M. Knapp, J. Małyszko, and S. Dobrzycki, “Intima-media thickness is a useful marker of the extent of coronary artery disease in patients with impaired renal function,” Atherosclerosis, vol. 202, no. 2, pp. 470–475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Hayashi, R. Shibata, H. Takahashi et al., “Association of adiponectin with carotid arteriosclerosis in predialysis chronic kidney disease,” American Journal of Nephrology, vol. 34, no. 3, pp. 249–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. M. Lemos, A. D. B. Jancikic, F. M. R. Sanches et al., “Intima-media thickness is associated with inflammation and traditional cardiovascular risk factors in non-dialysis-dependent patients with chronic kidney disease,” Nephron—Clinical Practice, vol. 115, no. 3, pp. c189–c194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Karakitsos, E. De Groot, A. P. Patrianakos et al., “Adiponectin and cardiovascular remodeling in end-stage renal disease and co-morbid diabetes mellitus,” American Journal of Nephrology, vol. 26, no. 4, pp. 340–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Ignacy, J. Chudek, M. Adamczak et al., “Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease—a follow-up study,” Nephron - Clinical Practice, vol. 101, no. 1, pp. c18–c24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Iordanidou, A. Tavridou, I. Petridis et al., “The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes,” Clinica Chimica Acta, vol. 411, no. 3-4, pp. 167–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. H. H. Parving, M. Mauer, and E. Ritz, Diabetic Nephropathy, WB Saunders, Boston, Mass, USA, 7th edition, 2004.
  28. K. Rossing, P. K. Christensen, P. Hovind, L. Tarnow, P. Rossing, and H.-H. Parving, “Progression of nephropathy in type 2 diabetic patients,” Kidney International, vol. 66, no. 4, pp. 1596–1605, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. National Kidney Foundation, “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, pp. S1–S266, 2002. View at Google Scholar
  30. K. Pawlak, M. Mysliwiec, and D. Pawlak, “Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio—are they real oxidative stress markers in dialyzed patients?” Life Sciences, vol. 92, no. 4-5, pp. 253–258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Mikami, T. Hamano, N. Fujii et al., “Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients,” Hypertension Research, vol. 31, no. 6, pp. 1163–1170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Vogt and D. Nagel, “Cluster analysis in diagnosis,” Clinical Chemistry, vol. 38, no. 2, pp. 182–198, 1992. View at Google Scholar · View at Scopus
  34. P. Stenvinkel, “Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation,” Journal of Renal Nutrition, vol. 21, no. 1, pp. 82–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Koshimura, H. Fujita, T. Narita et al., “Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy,” Biochemical and Biophysical Research Communications, vol. 316, no. 1, pp. 165–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Fujita, T. Morii, J. Koshimura et al., “Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy,” Endocrine Journal, vol. 53, no. 6, pp. 745–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Perri, D. Vizza, D. Lofaro et al., “Adiponectin is expressed and secreted by renal tubular epithelial cells,” Journal of Nephrology, vol. 26, no. 6, pp. 1049–1054, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Levin, B. Hemmelgarn, B. Culleton et al., “Guidelines for the management of chronic kidney disease,” Canadian Medical Association Journal, vol. 179, no. 11, pp. 1154–1162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. K. J. Lipska, C. J. Bailey, and S. E. Inzucchi, “Use of metformin in the setting of mild-to-moderate renal insufficiency,” Diabetes Care, vol. 34, no. 6, pp. 1431–1437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. S. H. A. Diepeveen, G. H. W. E. Verhoeven, J. van der Palen et al., “Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy,” Nephron - Clinical Practice, vol. 98, no. 1, pp. c3–c7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Kushiya, H. Wada, M. Sakakura et al., “Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis,” Clinical and Applied Thrombosis/Hemostasis, vol. 9, no. 3, pp. 203–210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Osorio, E. Ortega, T. De Haro, J. M. Torres, P. Sánchez, and E. Ruiz-Requena, “Lipid profiles and oxidative stress parameters in male and female hemodialysis patients,” Molecular and Cellular Biochemistry, vol. 353, no. 1-2, pp. 59–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. K. L. Johnson-Davis, C. Fernelius, N. B. Eliason, A. Wilson, S. Beddhu, and W. L. Roberts, “Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study,” Annals of Clinical and Laboratory Science, vol. 41, no. 4, pp. 331–339, 2011. View at Google Scholar · View at Scopus
  44. E. Sevinc Ok, F. Kircelli, G. Asci et al., “Neither oxidized nor anti-oxidized low-density lipoprotein level is associated with atherosclerosis or mortality in hemodialysis patients,” Hemodialysis International, vol. 16, no. 3, pp. 334–341, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Gustafsson, L. Lind, S. Söderberg, M. Zilmer, J. Hulthe, and E. Ingelsson, “Oxidative stress and inflammatory markers in relation to circulating levels of adiponectin,” Obesity, vol. 21, no. 7, pp. 1467–1473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. R. P. F. Dullaart, R. de Vries, A. van Tol, and W. J. Sluiter, “Lower plasma adiponectin is a marker of increased intimamedia thickness associated with type 2 diabetes mellitus and with male gender,” European Journal of Endocrinology, vol. 156, no. 3, pp. 387–394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. M. von Eynatten, D. Liu, C. Hock et al., “Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes,” Diabetes, vol. 58, no. 9, pp. 2093–2099, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Dursun, E. Dursun, G. Suleymanlar et al., “The effect of hemodialysis on accelerated atherosclerosis in diabetic patients: correlation of carotid artery intima-media thickness with oxidative stress,” Journal of Diabetes and Its Complications, vol. 23, no. 4, pp. 257–264, 2009. View at Publisher · View at Google Scholar · View at Scopus